A study of efficacy and safety of landiolol hydrochloride for pulmonary resection

A study of efficacy and safety of landiolol hydrochloride for pulmonary resection - A study of landiolol hydrochloride for pulmonary resection

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000029348

Enrollment

Registered

2017-10-01

Start date

2017-01-20

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

patients who underwent pulmonary resection

Interventions

landiolol hydrochloride placebo

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. male and female under 85 2. ASA 1-2 3. patients who underwent pulmonary resection due to lung cancer

Exclusion criteria

Exclusion criteria: 1. supraventricular arrhythmia including atrial fibrillation or atrial flutter 2. patients with sick sinus syndrome including patients with pacemaker implantation 3. patients with severe heart failure (Class III or higher NYHA cardiac function classification) 4. patients with second or higher degree atrioventricular block 5. moderate to severe valve disease 6. patients who have experienced acute cardiovascular events, cerebrovascular events, infectious inflammation within the past 60 days 7. patients with tendency of bradycardia (resting heart rate under 55 times/min) 8. patients with systolic blood pressure less than 80 mmHg 9. patients who had been administered beta blockers before surgery 10. patients with severe bronchial asthma 11. patients who had typical honeycomb lung due to obstructive pulmonary disease (COPD stage 2 or higher) or diffuse lung disease (IP) 12. patients whose cause of atrial fibrillation was identified as electrolyte abnormality, WPW syndrome or hyperthyroidism and so on 13. patients who had been administered antiarrhythmic drugs except for digitalis before pulmonary surgery 14. patients in whom beta-blockers are contraindicated 15. chronic inflammatory diseases 16. patients with severe hepatic impairment 17. patients with severe renal impairment 18. others, patients who are judged inappropriate for this study by principle investigator

Design outcomes

Primary

Measure	Time frame
2-year relapse free survival rate	—

Secondary

Measure	Time frame
Relapse free survival, overall survival	—

Countries

Japan

Contacts

Public ContactTomohiro Harada

Ono Pharmaceutical Co., Ltd. Clinical Development Planning 2

t.harada@ono.co.jp06-6263-3902

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026